MGTA

AcronymDefinition
MGTAMorris Garages Type a
MGTAMidwest Global Trade Association
MGTAMontana Growth Through Agriculture
MGTAMonroe-Gregg Teachers Association
References in periodicals archive ?
Like the technology alliance, MGTA provides seed capital.
CAMBRIDGE, Mass., April 29, 2019 -- Magenta Therapeutics (MGTA) announced it will present preclinical data on its small molecule/stem cell expansion program in an oral presentation on May 2 at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, D.C.
Celis has been asked to speak before numerous groups regarding trade, including: Cargo Logistics America in San Diego, California; the Mediterranean Anglo-American Business Network (MAABN) in Aix-en Provence and Marseille, France; the Midwest Global Trade Association (MGTA), in Minneapolis, MN; and the Xinji Chamber of Commerce in Hebei, China, on such issues as Exporting and Business Strategies During a Recession, INCOTERMS, Free Trade Agreements, Essential in Commercial Contracts, and Payment Terms in International Commercial Contracts; and NAFTA and the Trans-Pacific Partnership Agreement.
CAMBRIDGE, Mass., April 29, 2019 -- Magenta Therapeutics (MGTA) presented preclinical data on its small molecule/stem cell expansion program in an oral presentation recently at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, D.C.
CAMBRIDGE, Mass., February 21, 2019 -- Clinical stage biotech firm Magenta Therapeutics (MGTA) recently presented data from preclinical research on its MGTA-145 product candidate for stem cell mobilization at the Transplant and Cellular Therapy (TCT) annual meeting.
(NASDAQ: MGTA) has closed a public offering of 4,887,500 shares of its common stock, including 637,500 shares of common stock sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of USD 13.25 per share, the company said.
(NASDAQ: MGTA) has launched a proposed public offering of 4.25m shares of its common stock, the company said.
- US-based clinical-stage biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has dosed the first subjects in a Phase 1 study of MGTA-145, the company said.
- US-based clinical-stage biotechnology company Magenta Therapeutics (NASDAQ: MGTA) presented initial Phase 2 clinical data and preclinical research on its MGTA-456 program at the 60th annual meeting of the American Society of Hematology, the company said.
- US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) presented preclinical research on its targeted conditioning programmes at the 60th annual meeting of the American Society of Hematology, the company said.
- US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has strengthened its executive team with the appointment of Jason Ryan as chief operating and Financial officer, effective January 1, 2019, the company said.